Amicus Therapeutics Inc
$ 14.46
0.00%
22 Apr - close price
- Market Cap 4,540,450,000 USD
- Current Price $ 14.46
- High / Low $ 14.47 / 14.46
- Stock P/E N/A
- Book Value 0.88
- EPS -0.09
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.12 %
- 52 Week High 14.48
- 52 Week Low 5.51
About
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.
Analyst Target Price
$14.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-04 | 2025-07-31 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-10 |
| Reported EPS | 0.1 | 0.06 | -0.08 | 0.03 | 0.09 | -0.02 | -0.05 | -0.16 | -0.11 | -0.07 | -0.15 | -0.18 |
| Estimated EPS | 0.065 | 0.03 | -0.11 | -0.07 | 0.0911 | -0.01 | -0.06 | -0.07 | -0.06 | -0.08 | -0.12 | -0.15 |
| Surprise | 0.035 | 0.03 | 0.03 | 0.1 | -0.0011 | -0.01 | 0.01 | -0.09 | -0.05 | 0.01 | -0.03 | -0.03 |
| Surprise Percentage | 53.8462% | 100% | 27.2727% | 142.8571% | -1.2075% | -100% | 16.6667% | -128.5714% | -83.3333% | 12.5% | -25% | -20% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FOLD
2026-04-23 21:09:45
BioMarin Pharmaceutical Inc. has received French regulatory clearance for its merger with Amicus Therapeutics, satisfying the final condition for the transaction. The merger is now expected to close on April 27, 2026, with BioMarin showing strong financial health for the acquisition. This development follows recent news for BioMarin, including board changes, strategic decisions on drug development, and analyst ratings.
2026-04-23 20:09:45
Amicus Therapeutics (NASDAQ: FOLD) has received French regulatory clearance for its merger with BioMarin Pharmaceutical, satisfying the final major condition for the acquisition. The merger, under which Amicus will become a wholly-owned subsidiary of BioMarin, is now expected to close on April 27, 2026. This development removes a significant hurdle, though the companies note that forward-looking statements are subject to various risks and uncertainties.
2026-04-23 20:09:45
Amicus Therapeutics has received French foreign investment clearance for its merger with BioMarin, satisfying a key condition of the merger agreement. The companies anticipate the deal to officially close on April 27, 2026. This clearance marks the final condition met, other than standard closing-time conditions.
2026-04-23 14:08:50
Amicus Therapeutics (FOLD) stock reached a 52-week high of $14.48, reflecting a 104% increase over the past year due to strong investor confidence, 20% revenue growth, and 88.5% gross profit margins. The company's financial health has considerably strengthened, and analysts predict profitability this year. This surge coincides with the approval of its acquisition by BioMarin Pharmaceutical and upcoming presentations of new data on its rare disease treatments.
2026-04-23 09:08:50
This article is a placeholder with a title indicating that California biotech BioMarin will acquire Amicus Therapeutics, a rare-disease company with ties to Philadelphia, for $4.8 billion. The content of the article itself is missing, showing only "MSN". More information would be needed to provide a full summary of the acquisition details, reasons, and potential impacts.
2026-04-21 04:09:30
Amicus Therapeutics Inc. (FOLD) shows neutral near and mid-term readings but a positive long-term bias, according to AI models. The analysis highlights a 32.5:1 risk-reward setup targeting a 9.3% gain with minimal risk. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are provided, along with multi-timeframe signal analysis for FOLD.
